

EQA round: KM1/25 - Cardiac Markers

Deadline: 21.3.2025

Setup: Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(218) CK-MB mass	[µg/L]				10							8	8	100
Sample A1		35,1	4,9	14	10							8	8	100
(60) Roche		33,4	0,82	2,4	5	0	CVPG	33,1	0,7	27%	24,1	42,1	5	
Other					5	0							3	
							1x 1, 2x 12, 1x 61, 1x 179							
Sample B1		75,5	12	16	10							8	8	100
(60) Roche		71	2,1	3	5	0	CVPG	70,1	2	27%	51,1	89,1	5	
Other					5	0							3	
							1x 1, 2x 12, 1x 61, 1x 179							
(444) Homocysteine	[µmol/L]				26							24	18	75
Sample A1		3,05	0,86	28	26							24	18	75
(1) Abbott		3,19	0,13	4,2	5	0	CVPG	3,34	0,15	20%	2,67	4,01	5	
(60) Roche		4,03	0,44	11	5	0	CVPG	4,05	0,12	20%	3,24	4,86	5	
(109) Axis-Shield		2,75	0,36	13	12	0	CVPG	2,8	0,11	20%	2,24	3,36	12	
Other					4	0							2	
							1x 75, 2x 179, 1x 999							
Sample B1		3,06	0,86	28	26							24	19	79
(1) Abbott		3,33	0,22	6,5	5	0	CVPG	3,43	0,16	20%	2,74	4,12	5	
(60) Roche		4	0,3	7,4	5	0	CVPG	4,01	0,12	20%	3,2	4,82	5	
(109) Axis-Shield		2,74	0,35	13	12	0	CVPG	2,73	0,14	20%	2,18	3,28	12	
Other					4	0							2	
							1x 75, 2x 179, 1x 999							
(441) Myoglobin	[µg/L]				26							25	25	100
Sample A1		204	14	6,7	26							25	25	100
(1) Abbott		213	28	13	5	0	CVPG	230	11	22%	179	281	5	
(60) Roche		206	8	3,9	16	0	CVPG	205	2,2	22%	159	251	16	
Other					5	0							4	
							3x 12, 1x 178, 1x 179							
Sample B1		396	29	7,3	26							25	25	100
(1) Abbott		424	79	19	5	0	CVPG	467	26	22%	364	570	5	
(60) Roche		398	22	5,6	16	0	CVPG	399	5,1	22%	311	487	16	
Other					5	0							4	
							3x 12, 1x 178, 1x 179							
(447) NT-proBNP	[ng/L]				53							49	47	96
Sample A1		566	65	11	53							49	47	96
(1) Abbott		638	24	3,8	9	0	CVPG	638	12	27%	465	811	9	
(60) Roche		535	22	4	38	0	CVPG	529	6,7	27%	386	672	38	
Other					6	0							2	
							1x 12, 1x 15, 1x 54, 2x 61, 1x 179							
Sample B1		1190	190	16	53							49	47	96
(1) Abbott		1420	61	4,3	9	0	CVPG	1410	25	27%	1020	1800	9	
(60) Roche		1100	47	4,3	38	0	CVPG	1100	14	27%	803	1400	38	
Other					6	0							2	
							1x 12, 1x 15, 1x 54, 2x 61, 1x 179							
(442) Troponin I	[ng/L]				16							16	15	94
Sample A1		9,64	5,7	60	16							16	15	94
(1) Abbott		11,7	2,1	18	5	0	CVPG	13,2	0,36	27%	9,63	16,8	5	
(12) Beckman Coulter		5,5	2,1	38	8	0	CVPG	5,77	0,58	±2,7	3,07	8,47	8	
Other					3	0							3	
							1x 54, 2x 179							
Sample B1		144	99	69	16							16	16	100
(1) Abbott		227	8	3,5	5	0	CVPG	229	6,6	27%	167	291	5	
(12) Beckman Coulter		64,1	12	19	8	0	CVPG	65,5	4,1	27%	47,8	83,2	8	
Other					3	0							3	
							1x 54, 2x 179							
(443) Troponin T	[ng/L]				39							38	38	100
Sample A1		27,4	1,6	5,8	39							38	38	100
(2) Immunochemical methods (hs); (60) Roche		27,5	1,5	5,5	38	0	CVPG	27,8	0,34	22%	21,6	34	38	
Other					1	0							0	
							1x 1/61							
Sample B1		234	15	6,6	39							38	38	100
(2) Immunochemical methods (hs); (60) Roche		235	15	6,3	38	0	CVPG	237	3,4	22%	184	290	38	

EQA round: KM1/25 - Cardiac Markers

Deadline: 21.3.2025

Setup: Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Other					1	0	1x 1/61					0		
Set 2														
(449) BNP	[ng/L]				4							1	1	100
Sample A2		81,4	99	120	4							1	1	100
Other					4	0	1x 1, 1x 12, 1x 179, 1x 999					1		
Sample B2		1680	1800	100	4							1	1	100
Other					4	0	1x 1, 1x 12, 1x 179, 1x 999					1		